SAC Capital Raises Stake in Repros Therapeutics (RPRX) to 5.16%
Tweet Send to a Friend
Up)
In a 13G filing on Repros Therapeutics (NASDAQ: RPRX), Steven A. Cohen's hedge fund SAC Capital disclosed a 5.16%, or 883,207 share, stake in the company. This is up 1,489.30% from the 55,572 shares held at the end of the latest quarter ending September 30, 2012.
For more notable holders of REPROS THERAPEUTICS stock click here. For more information on SAC Capital click here.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
For more notable holders of REPROS THERAPEUTICS stock click here. For more information on SAC Capital click here.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- Dan Loeb Builds Massive Stake in Sony (SNE), Wants Entertainment Arm Split
- Griffin's Blue Ridge Capital Enters CBS (CBS), Citigroup (C), Netflix (NFLX); Exits Apple (AAPL)
- Rosenstein's JANA Partners Sells Entire 1M Share Stake in Neflix (NFLX)
Create E-mail Alert Related Categories
13Gs, Hedge FundsRelated Entities
SAC Capital, Steven A. Cohen, Hedge Funds, 13G
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
